We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Eden Biodesign and Onyvax Limited Announce Biomanufacturing Contract

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eden Biodesign and Onyvax Limited Announce Biomanufacturing Contract"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Eden Biodesign, the operator of the UK National Biomanufacturing Centre (NBC), and Onyvax Limited have announced a commercial agreement where Eden will supply cGMP clinical manufacturing services to Onyvax for its Cell Vaccine program in ovarian cancer.

The NBC Access Fund, a £2.7 million fund launched by the Northwest Regional Development Agency (NWDA) will provide supporting finance for the programme which will take place at the NBC, in Speke, Liverpool. It is the first programme to be awarded financial support.

The access funding allows Onyvax to take advantage of the development and manufacturing expertise of Eden Biodesign, which was appointed by the NWDA to run the NBC, a £34.25m initiative to provide state of the art biomanufacturing facilities and development expertise to UK Small and Medium sized Enterprises (SMEs) and academics. The NBC opened for business in February 2006.

With a client base of over 70 biotech organizations, Eden Biodesign specialises in overcoming technical, regulatory and logistical hurdles, speeding up biopharmaceutical development timelines and reducing cost.

Crawford Brown, CEO of Eden Biodesign, said: “We are delighted to have the opportunity to work with Onyvax, a top tier UK Biotech and are convinced we will be able to add substantial clinical and commercial value to their products.”

Anthony Walker, of Onyvax, commented: “This agreement marks an important step in the development of Onyvax’s pipeline. This ovarian cancer vaccine is based on the same technology as Onyvax-P, the company’s lead product for prostate cancer that has generated encouraging results in Phase IIa clinical trials. We hope to roll out the technology to a range of other cancers over the next few years and hope to start clinical trials in ovarian cancer in 2007/2008.”

Dr Linda Magee, NBC Project Director for NWDA, also commented: “We are delighted to be delivering genuine practical assistance to UK biotechs in meeting the stringent requirements for manufacture of clinical products through the support of the NBC programme. Onyvax has an exciting product technology that could in future deliver huge benefits to cancer patients worldwide”.